Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

Taishi Harada, A. Lopez-Chavez, L. Xi, M. Raffeld, Y. Wang, G. Giaccone

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.

Original languageEnglish
Pages (from-to)1744-1752
Number of pages9
JournalOncogene
Volume30
Issue number15
DOIs
Publication statusPublished - Apr 14 2011

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
African Americans
Mutation
Exons
Insertional Mutagenesis
Protein-Tyrosine Kinases
Mutation Rate
Point Mutation
Phosphotransferases
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. / Harada, Taishi; Lopez-Chavez, A.; Xi, L.; Raffeld, M.; Wang, Y.; Giaccone, G.

In: Oncogene, Vol. 30, No. 15, 14.04.2011, p. 1744-1752.

Research output: Contribution to journalArticle

Harada, Taishi ; Lopez-Chavez, A. ; Xi, L. ; Raffeld, M. ; Wang, Y. ; Giaccone, G. / Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. In: Oncogene. 2011 ; Vol. 30, No. 15. pp. 1744-1752.
@article{fd1778bf22ae4a57871853950a1dac9b,
title = "Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry",
abstract = "Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.",
author = "Taishi Harada and A. Lopez-Chavez and L. Xi and M. Raffeld and Y. Wang and G. Giaccone",
year = "2011",
month = "4",
day = "14",
doi = "10.1038/onc.2010.545",
language = "English",
volume = "30",
pages = "1744--1752",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "15",

}

TY - JOUR

T1 - Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

AU - Harada, Taishi

AU - Lopez-Chavez, A.

AU - Xi, L.

AU - Raffeld, M.

AU - Wang, Y.

AU - Giaccone, G.

PY - 2011/4/14

Y1 - 2011/4/14

N2 - Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.

AB - Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79954574430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954574430&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.545

DO - 10.1038/onc.2010.545

M3 - Article

C2 - 21132006

AN - SCOPUS:79954574430

VL - 30

SP - 1744

EP - 1752

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 15

ER -